Next, we observed frequent amplification of the FOXP2 gene, which occurred in 15–20% of primary prostate tumors from the Broad/Cornell (Baca et al., 2013) and TCGA datasets and in 25% of metastatic tumors from the SU2C dataset (Robinson et al., 2015; Figure 1—figure supplement 4B). The gene discussed is FOXP2; the disease is prostate neoplasm.